In addition to having a panel of leaders that have proven their mettle in clinical expertise and management, IHH has a comprehensive set of policies and systems to ensure the highest level of governance in board diversity, anti-corruption and data privacy and protection. Our strict policies foster trust and positively influence the value that IHH delivers to stakeholders year after year. Delivering Results In recognition of the steadfast confidence our shareholders have placed in IHH, the Board of Directors declared a final cash dividend of 5.5 sen per share to be paid on 26 April 2024, bringing total ordinary dividend for FY2023 to 9.0 sen per share (previously paid interim cash dividend of 3.5 sen per share on 27 October 2023). The total dividend declared for FY2023 amounts to 18.6 sen per share, including a special dividend of 9.6 sen per share paid in end June 2023 from the divestment of International Medical University (IMU). Furthermore, the Group enhanced its dividend policy in February 2024, whereby not less than 30% of the Group’s profit after tax and minority interests, excluding exceptional items, shall be distributed to shareholders. These dividends signify not only our financial strength but also our commitment to delivering consistent returns to our valued shareholders. Looking Ahead There is much to be excited about in 2024 and beyond. The use of technology in healthcare – from telemedicine and artificial intelligence to augmented and virtual reality – will continue to proliferate across patient care and medical training. Personalised medicine and preventive healthcare, along with increased discernment among consumers will positively move the needle towards better population well-being in the long run. While the wider landscape continues to pose business uncertainties, IHH will be meeting challenges ahead with prudence and cautious optimism as one IHH Group, while continuing our march to Care. For Good. We have built a leading presence in our core markets of Malaysia, Singapore, Türkiye and India. While we continue to deepen our reach in these core countries, we will evaluate opportunities in new high-growth markets to bring IHH’s value-driven clinical services to even more individuals around the world. We sincerely appreciate your ongoing support and trust in IHH. Tan Sri Mohd Azlan Hashim Non-Executive Chairman Sustainability is an ongoing journey that is in equal parts complex, urgent and purposeful. IHH remains open to new and better ways to enhance our sustainability efforts, and we hope to inspire change by being a trailblazer in the healthcare sector. Delivering Value Through Our Governance We are delighted to announce the appointment of IHH Healthcare’s new Group Chief Executive Officer Dr Prem Kumar Nair, who officially stepped into the role on 1 October 2023. He is a familiar face to us all, having helmed IHH Singapore in the last three and a half years. Dr Nair is a highly regarded industry veteran, having had a wealth of experience in clinical work, healthcare administration and management, and education. I look forward to working closely with him, the IHH management team, and all our stakeholders to continue IHH’s sustainable growth, astute innovativeness, and all-round excellence. At this juncture, I would also like to express my gratitude to IHH’s Transition Committee for their work prior to Dr Nair’s appointment and seeing to the smooth changeover. Additionally, we have appointed a new Group Chief Financial Officer, Mr Dilip Kadambi, as of 5 April 2024. He will play a pivotal role in providing financial leadership for IHH and its operations, ensuring a path of continued success and growth for the organisation. In board movements, we welcome Mr Yoichiro Endo, who will assume the role of Non-Independent, Non-Executive Director taking over from Mr Takeshi Akutsu, as of 1 April 2024. Annual Report 2023 25
RkJQdWJsaXNoZXIy NDgzMzc=